Search
COPD Paid Clinical Trials in South Carolina
A listing of 8 COPD clinical trials in South Carolina actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 8 of 8
The state of South Carolina currently has 8 active clinical trials seeking participants for COPD research studies. These trials are conducted in various cities, including Charleston, Greenville, Spartanburg and Columbia.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Respiratory Syncytial Virus (RSV) Treatment Study
Recruiting
We’re seeking volunteers to participate in a RSV treatment study.
Our site is now enrolling ages 18+ years old in a research study evaluating an investigational RSV treatment. Compensation is available for participation. To be eligible, you must be 18 or older, experiencing current symptoms (such as nasal congestion, cough, or wheezing), and meet at least one of the following:
- Asthma
- Chronic lung disease
- COPD
- Heart disease
- Age 60 or older
Our site is now enrolling ages 18+ years old in a research study evaluating an investigational RSV treatment. Compensation is available for participation. To be eligible, you must be 18 or older, experiencing current symptoms (such as nasal congestion, cough, or wheezing), and meet at least one of the following:
- Asthma
- Chronic lung disease
- COPD
- Heart disease
- Age 60 or older
Conditions:
RSV
Respiratory Syncytial Virus (RSV)
Healthy
Healthy Volunteers
Healthy Subjects
Featured Trial
Respiratory Syncytial Virus (RSV) Treatment Study
Recruiting
We’re seeking volunteers to participate in a RSV treatment study.
Our site is now enrolling ages 18+ years old in a research study evaluating an investigational RSV treatment. Compensation is available for participation. To be eligible, you must be 18 or older, experiencing current symptoms (such as nasal congestion, cough, or wheezing), and meet at least one of the following:
- Asthma
- Chronic lung disease
- COPD
- Heart disease
- Age 60 or older
Our site is now enrolling ages 18+ years old in a research study evaluating an investigational RSV treatment. Compensation is available for participation. To be eligible, you must be 18 or older, experiencing current symptoms (such as nasal congestion, cough, or wheezing), and meet at least one of the following:
- Asthma
- Chronic lung disease
- COPD
- Heart disease
- Age 60 or older
Conditions:
RSV
Respiratory Syncytial Virus (RSV)
Healthy
Healthy Volunteers
Healthy Subjects
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Evaluation of Auto-EPAP for Management of Upper Airway Obstruction During Non-Invasive Ventilation
Recruiting
To evaluate the safety and effectiveness of the Automatic Expiratory Positive Airway Pressure (Auto-EPAP) feature versus manual expiratory positive airway pressure (EPAP) in the Vivo 45 LS Ventilator.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Bogan Sleep Consultants, Columbia, South Carolina
Conditions: Obstructive Sleep Apnea, Obesity Hypoventilation Syndrome (OHS), Chronic Obstructive Pulmonary Disease (COPD), Neuromuscular Diseases (NMD)
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
04/03/2025
Locations: Medtrial, LLC, Columbia, South Carolina +2 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
03/31/2025
Locations: Research Site, Anderson, South Carolina +4 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
03/31/2025
Locations: Research Site, Rock Hill, South Carolina
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD
Recruiting
The purpose of this study is to demonstrate that the lung function effect from orally inhaled BGF delivered via HFO propellant is equivalent to the lung function effect from orally inhaled BGF delivered via HFA propellant in participants with COPD. The study duration for each participant will be approximately 15 to 16 weeks and consist of:
1. A screening and placebo run-in period of approximately 2 weeks prior to first dosing
2. Three treatment periods of approximately 4 weeks each (one period... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
03/26/2025
Locations: Research Site, Gaffney, South Carolina
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Recruiting
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.
Gender:
ALL
Ages:
Between 40 years and 130 years
Trial Updated:
03/14/2025
Locations: Research Site, Rock Hill, South Carolina
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
Recruiting
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
02/20/2025
Locations: Research Site 023, Anderson, South Carolina +5 locations
Conditions: COPD
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/23/2024
Locations: Research Site, Anderson, South Carolina +5 locations
Conditions: COPD (Chronic Obstructive Pulmonary Disease)